The three-year award from the National Institute for Health and Care Research will support finalization of the test as well as initial validation studies.

Last week, readers were most interested in a story about the FDA's decision not to appeal a court decision vacating the agency's LDT rule.

The test is the last of three multiplex bloodstream infection panels that the firm has designed for its Liaison Plex molecular testing instrument.